Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CL-108 5 mg for Pain and OINV after Bunionectomy
NCT03657810Phase 3Completed
- Sponsor
- Charleston Laboratories, Inc.
- Start
- Aug 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydrocodone + acetaminophen + promethazine in acute pain and Opioid-induced nausea and vomiting (OINV) (3 arms), sponsored by Charleston Laboratories, Inc. Primary endpoints: Percentage of Participants With OINV Over 48 Hours and The Sum of Pain Intensity Differences (on PI-NRS) Over 48 Hours. Started Aug 2017; status: completed.
02
Drugs
hydrocodone + acetaminophen + promethazine
03
Conditions
acute painOpioid-induced nausea and vomiting (OINV)
Beyond the preview
Go deeper on NCT03657810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657810.